Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study

被引：8
|
作者：
Moreau, Philippe [1 ]
Ghori, Razi [2 ]
Farooqui, Mohammed [2 ]
Marinello, Patricia [2 ]
San Miguel, Jesus [3 ]
机构：
[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[2] Merck & Co Inc, Dept Med Oncol, Kenilworth, NJ USA
[3] Clin Univ Navarra, CIMA, IDISNA, CIBERONC,Dept Clin & Translat Med, Pamplona, Spain
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 01期
关键词：
multiple myeloma; immunotherapy; oncology; IMMUNOTHERAPY;
D O I：
10.1111/bjh.17448
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E48 / E51
页数：4
相关论文
共 50 条
  • [21] Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Chari, Ajai
    Girnius, Saulius
    Chhabra, Saurabh
    Cornell, Robert Frank
    Gasparetto, Cristina J.
    Karanes, Chatchada
    Lunning, Matthew A.
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Shustik, Chaim
    Stuart, Robert K.
    Lih, Jason
    Lee, Yihua
    Salman, Zeena
    Graef, Thorsten
    Valent, Jason
    BLOOD, 2017, 130
  • [22] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Costa, Luciano J.
    Davies, Faith E.
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Hong, Wan-Jen
    Dail, Monique
    Salem, Ahmed Hamed
    Yang, Xiaoqing
    Masud, Abdullah A.
    Munasinghe, Wijith
    Ross, Jeremy A.
    Bueno, Orlando F.
    Kumar, Shaji K.
    Stadtmauer, Edward A.
    BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
  • [23] Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Stadtmauer, Edward A.
    Morgan, Gareth
    Monohan, Gregory
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Mobasher, Mehrdad
    Freise, Kevin J.
    Ross, Jeremy A.
    Pesko, John
    Munasinghe, Wijith
    Gudipati, Saketh
    Mudd, Sarah
    Bueno, Orlando
    Kumar, Shaji K.
    BLOOD, 2018, 132
  • [24] A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
    Vesole, David H.
    Siegel, David Samuel DiCapua
    Richter, Joshua Ryan
    McNeill, Ann
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    McBride, Laura
    Raucci, Laura
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Smith, Judith
    Mato, Anthony R.
    Bilotti, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
    Manasanch, Elisabet E.
    Shah, Jatin J.
    Lee, Hans C.
    Weber, Donna M.
    Thomas, Sheeba K.
    Amini, Behrang
    Olsem, Jasper
    Crumpton, Brandon
    Morphey, Ashley
    Berkova, Zuzana
    Feng, Lei
    Orlowski, Robert Z.
    HAEMATOLOGICA, 2020, 105 (05) : E242 - E245
  • [26] Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Kumar, Shaji K.
    Grzasko, Norbert
    Delimpasi, Sosana
    Jedrzejczak, Wieslaw W.
    Grosicki, Sebastian
    Kyrtsonis, Marie-Christine
    Spencer, Andrew
    Gupta, Neeraj
    Teng, Zhaoyang
    Byrne, Catriona
    Labotka, Richard
    Dimopoulos, Meletios A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (04) : 536 - 546
  • [27] A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Khouri, Jack
    Faiman, Beth
    Wei, Wei
    Grabowski, Dale
    Samaras, Christy Joy
    Mahfouz, Reda
    Lazarus, Hillard
    Dean, Robert
    Malek, Eshan
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Rosko, Nathaniel
    Fada, Sherry
    Kalaycio, Matt
    Liu, Hien
    Saunthararajah, Yogen
    Chew, Yap
    Valent, Jason
    Reu, Frederic
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E262 - E263
  • [28] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Lu, Rebecca
    Morphey, Ashley
    Crumpton, Brandon
    Patel, Krina K.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [29] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    Blood Cancer Journal, 9
  • [30] A phase lb multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed multiple myeloma - preliminary results
    Niesvizky, R.
    Wang, M.
    Bensinger, B.
    Vallone, M.
    Gutierrez, A. A.
    Kauffman, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 569 - 569
12345